Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
申请人:Sah Dinah Wen-Yee
公开号:US20110184046A1
公开(公告)日:2011-07-28
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3.
Use of a GSK-3 Inhibitor to Maintain Potency of Cultured Cells
申请人:Mays Robert W.
公开号:US20120009674A1
公开(公告)日:2012-01-12
The present invention is directed to the culture of non-embryonic cells, that can differentiate into cell types of more than one embryonic lineage, in culture under conditions that maintain differentiation capacity during expansion; more particularly, culturing non-embryonic cells in the presence of at least one GKS-3 inhibitor, such as BIO.
VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS
申请人:Frequency Therapeutics, Inc.
公开号:US20220133740A1
公开(公告)日:2022-05-05
The present invention provides methods for treating diseases and disorders of the ear with valproic acid compounds and Wnt agonists. The present invention further provides kits for the same.
HYDROGEL DRUG DELIVERY COMPOSITION
申请人:Board of Regents of the University of Nebraska
公开号:US20220218571A1
公开(公告)日:2022-07-14
Disclosed is a hydrogel drug delivery composition comprising a therapeutic agent and a poloxamer, wherein the poloxamer is modified to be capable of adhering to a surface of bones or teeth, and wherein the poloxamer is modified by pyrophosphate, bisphosphonates, acidic peptides or tetracycline and its derivatives.